Proteasome Inhibitor CEP 18770
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Enzyme Inhibitor ->
Proteasome Inhibitor -> Proteasome Inhibitor CEP 18770
Proteasome Inhibitor CEP 18770 Definition
An orally bioavailable synthetic P2 threonine boronic acid inhibitor of the chymotrypsin-like activity of the proteasome, with potential antineoplastic activity. Proteasome inhibitor CEP 18770 represses the proteasomal degradation of a variety of proteins, including inhibitory kappaBalpha (IkappaBalpha), resulting in the cytoplasmic sequestration of the transcription factor NF-kappaB; inhibition of NF-kappaB nuclear translocation and transcriptional up-regulation of a variety of cell growth-promoting factors; and apoptotic cell death in susceptible tumor cell populations. In vitro studies indicate that this agent exhibits a favorable cytotoxicity profile toward normal human epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells relative to the proteasome inhibitor bortezomib. The intracellular protein IkappaBalpha functions as a primary inhibitor of the proinflammatory transcription factor NF-kappaB.
Proteasome Inhibitor CEP 18770 Synonyms
Proteasome Inhibitor CEP 18770, CEP 18770
Terms in Proteasome Inhibitor CEP 18770 category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.